Modeling the effect of 3 missense AGXT mutations on dimerization of the AGT enzyme in primary hyperoxaluria type 1

Journal of Nephrology

Volumn 23, Issue 6, 2010, Pages 667-676

  Robbiano, Angela ^a   Frecer, Vladimir ^b   Miertus, Jan ^c   Zadro, Cristina ^d   Ulivi, Sheila ^d   Bevilacqua, Elena ^d   Mandrile, Giorgia ^a   De Marchi, Mario ^a   Miertus, Stanislav ^e   Amoroso, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e UNIDO   (Italy)

Author keywords

AGT enzyme; AGXT gene; Molecular modeling; Primary hyperoxaluria type 1

Indexed keywords

ALANINE GLYOXYLATE AMINOTRANSFERASE; PYRIDOXINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CHEMICAL STRUCTURE; CHILD; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; DIMERIZATION; FEMALE; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; MALE; MISSENSE MUTATION; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; OXALOSIS 1; PATHOGENESIS; PRESCHOOL CHILD; THERMODYNAMICS; THREE DIMENSIONAL IMAGING; WILD TYPE;

AMINO ACID SEQUENCE; FEMALE; HUMANS; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PROTEIN MULTIMERIZATION; TRANSAMINASES;

EID: 78549279499     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Purdue PE, Lumb MJ, Fox M, et al. Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics. 1991;10:34-42.
2. Marangella M, Petrarulo M, Vitale C, et al. The primary hyperoxalurias. Contrib Nephrol. 2001;136:11-32.
3. Danpure CJ, Jennings PR. Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett. 1986;201:20-24. (Pubitemid 16072347)
4. Milliner DS, Wilson DM, Smith LH. Clinical expression and long-term outcomes of primary hyperoxaluria types 1 and 2. J Nephrol. 1998;11(Suppl 1):56-59.
5. Milliner DS. The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol. 2005;25:154-160.
6. Williams E, Rumsby G. Selected exonic sequencing of the AGXT gene provides a genetic diagnosis in 50% of patients with primary hyperoxaluria type 1. Clin Chem. 2007;53:1216-1221. (Pubitemid 47020976)
7. Rumsby G, Williams E, Coulter-Mackie M. Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. Kidney Int. 2004;66:959-963. (Pubitemid 39120998)
8. Monico CG, Rossetti S, Schwanz HA, et al. Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis. J Am Soc Nephrol. 2007;18:1905-1914. (Pubitemid 46870327)
9. Danpure CJ, Jennings PR, Watts RW. Enzymological diagnosis of primary hyperoxaluria type 1 by measurement of hepatic alanine: glyoxylate aminotransferase activity. Lancet. 1987;1:289-291. (Pubitemid 17009788)
10. Williams EL, Acquaviva C, Amoroso A, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat. 2009;30:910-917.
11. Danpure CJ, Cooper PJ, Wise PJ, Jennings PR. An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. J Cell Biol. 1989;108:1345-1352.
12. Purdue PE, Allsop J, Isaya G, Rosenberg LE, Danpure CJ. Mistargeting of peroxisomal L-alanine:glyoxylate aminotransferase to mitochondria in primary hyperoxaluria patients depends upon activation of a cryptic mitochondrial targeting sequence by a point mutation. Proc Natl Acad Sci USA. 1991;88:10900-10904. (Pubitemid 21915946)
13. Purdue PE, Takada Y, Danpure CJ. Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol. 1990;111:2341-2351. (Pubitemid 120014519)
14. Lumb MJ, Danpure CJ. Functional synergism between the most common polymorphism in human alanine:glyoxylate aminotransferase and four of the most common disease-causing mutations. J Biol Chem. 2000;275:36415-36422.
15. van Woerden CS, Groothoff JW, Wijburg FA, Annink C, Wanders RJ, Waterham HR. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int. 2004;66:746-752. (Pubitemid 38982018)
16. Amoroso A, Pirulli D, Florian F, et al. AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol. 2001;12:2072-2079.
17. Monico CG, Olson JB, Milliner DS. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am J Nephrol. 2005;25:183-188.
18. Purdue PE, Lumb MJ, Allsop J, Minatogawa Y, Danpure CJ. A glycine-to-glutamate substitution abolishes alanine:glyoxylate aminotransferase catalytic activity in a subset of patients with primary hyperoxaluria type 1. Genomics. 1992;13:215-218.
19. Zhang X, Roe SM, Hou Y, et al. Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1. J Mol Biol. 2003;331:643-652. (Pubitemid 36937151)
20. Danpure CJ. Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transplant. 2005;20:1525-1529.
21. Pirulli D, Puzzer D, Ferri L, et al. Molecular analysis of hyperoxaluria type 1 in Italian patients reveals eight new mutations in the alanine: glyoxylate aminotransferase gene. Hum Genet. 1999;104:523-525. (Pubitemid 29370930)
22. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863-874. (Pubitemid 32447869)
23. Yue P, Moult J. Identification and analysis of deleterious human SNPs. J Mol Biol. 2006;356:1263-1274. (Pubitemid 43199928)
24. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, Orozco M. PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics. 2005;21:3176-3178. (Pubitemid 41418475)
25. Pirulli D, Marangella M, Amoroso A. Primary hyperoxaluria: genotype-phenotype correlation. J Nephrol. 2003;16:297-309.
26. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28:235-242.
27. Maple J, Hwang M, Stockfish T, et al. Derivation of class II force fields: Part 1: methodology and quantum force field for the alkyl functional group and alkane molecules. J Comput Chem. 1994;15:162-182.
28. Gilson MK, Honig B. The inclusion of electrostatic hydration energies in molecular mechanics calculations. J Comput Aided Mol Des. 1991;5:5-20.
29. Connolly ML. Solvent-accessible surfaces of proteins and nucleic acids. Science. 1983;221:709-713.
30. Leiper JM, Oatey PB, Danpure CJ. Inhibition of alanine:glyoxylate aminotransferase 1 dimerization is a prerequisite for its peroxisome-to- mitochondrion mistargeting in primary hyperoxaluria type 1. J Cell Biol. 1996;135:939-951. (Pubitemid 26403770)
31. Burnett JC, Botti P, Abraham DJ, Kellogg GE. Computationally accessible method for estimating free energy changes resulting from site-specific mutations of biomolecules: systematic model building and structural/hydropathic analysis of deoxy and oxy hemoglobins. Proteins. 2001;42:355-377.
32. Kobayashi Y, Nakajima T, Inoue I. Molecular modeling of the dimeric structure of human lipoprotein lipase and functional studies of the carboxyl-terminal domain. Eur J Biochem. 2002;269:4701-4710.